Saturday 17 October 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 13.8%, free cash flow fell 17.3% and total debt rose 4.31%, each against the same quarter a year earlier.
27.82
1.82
−6.14%
Follow PHVS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (71.50%) | (76.21%) | (66.63%) | (52.30%) |
+8 more TTM periods Free account |
|
| (64.43%) | (69.28%) | (60.57%) | (48.83%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(57.28%) | (71.08%) | (65.02%) | (49.63%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.62) | (2.63) | (2.62) | (2.45) | |
Free Cash Flow |
(178.14) | (171.71) | (155.27) | (152.55) | |
Capital Expenditures |
(0.11) | (0.08) | (0.19) | (0.36) | |
| Other line items | |||||
Cash ROIC |
(24.73%) | (30.32%) | (24.35%) | (20.33%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.89 | 0.88 | 0.78 | 0.84 | |
Depreciation/Fixed assets |
0.89 | 0.64 | 0.65 | 0.57 | |
Capex/Depreciation |
(0.20) | (0.16) | (0.39) | (0.78) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.62) | (2.63) | (2.62) | (2.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates